Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

HPV-Related Carcinoma: early-phase trial registry

6 of 11 indexed HPV-Related Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count

HPV-Related Carcinoma: 11 US clinical trials tracked, 6 recruiting.

HPV-Related Carcinoma is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Christian Hinrichs, running 2 of these trials.

Enrollment posture brief

Registry condition hpv-related-carcinoma

OPEN 6 | RECR 55% | LATE 0 | EARLY 8 | RANK #1577 | SPON 2

Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)

Acute Pancreatitis81.8%HPV-Related Carcinoma (this)55%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near HPV-Related Carcinoma

HPV-Related Carcinoma lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for HPV-Related Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. HPV-Related Carcinoma is recruiting above its size-band peers.

    6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates HPV-Related Carcinoma research.

    Christian Hinrichs accounts for 2 of 11 trials (18.2%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most HPV-Related Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 20 among the 11 trials that report a genuine target (sentinel values excluded). 8 of those (72.7%) plan for fewer than 100 participants.

  4. HPV-Related Carcinoma research is mostly interventional.

    8 interventional and 3 observational studies make up this index (72.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 24

Open and recent trials

11 total, page 1 of 1

RECRUITING 400 participants

Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)

H. Lee Moffitt Cancer Center and Research Institute

NCT06305676

RECRUITING Phase 2 46 participants

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Precigen

NCT06157151

RECRUITING Phase 2 30 participants

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

Memorial Sloan Kettering Cancer Center

NCT05307939

RECRUITING Phase 2 20 participants

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Christian Hinrichs

NCT05686226

RECRUITING 20 participants

Detecting HPV DNA in Anal and Cervical Cancers

University of Chicago

NCT04857528

RECRUITING Phase 1 15 participants

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Christian Hinrichs

NCT05639972

ACTIVE NOT RECRUITING Phase 1 840 participants

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

TScan Therapeutics

NCT05973487

ACTIVE NOT RECRUITING Phase 1 143 participants

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Transgene

NCT03260023

ACTIVE NOT RECRUITING Phase 2 19 participants

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

University of Michigan Rogel Cancer Center

NCT06234748

ACTIVE NOT RECRUITING Phase 1 12 participants

IBRX-042 In Participants With HPV-Associated Tumors

ImmunityBio

NCT05976828

ACTIVE NOT RECRUITING 9 participants

A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

Memorial Sloan Kettering Cancer Center

NCT05814549

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4

Named interventions

Most-linked intervention names on HPV-Related Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

E7 TCR-T cells Biological
2 trials
Aldesleukin Drug
2 trials
IBRX-042 Drug
1 trials
TG4001 Biological
1 trials
Tsc-204-a0201 + Tsc-200-a0201 Biological
1 trials
Tsc-204-a0201 + Tsc-204-c0702 Biological
1 trials
TSC-200-A0201 Biological
1 trials
TSC-204-C0702 Biological
1 trials

US sites by state

Facility locations filed on HPV-Related Carcinoma trials. A trial with sites in several states counts in each.

New Jersey 4 trials
Florida 4 trials
New York 3 trials
Pennsylvania 2 trials
Minnesota 2 trials
Michigan 2 trials
Maryland 2 trials
Illinois 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this HPV-Related Carcinoma page

11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 6 HPV-Related Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Christian Hinrichs sponsors the most HPV-Related Carcinoma trials on record, review their full trial history before evaluating a specific study. See Christian Hinrichs's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HPV-Related Carcinoma condition card totals 11 registered trials; most-linked intervention E7 TCR-T cells; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.